Eiger BioPharmaceuticals “announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy, or lonafarnib., a treatment for Hutchinson-Gilford progeria syndrome, HGPS, and processing deficient progeroid laminopathy (PDPL). The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years in children and young adults with HGPS.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EIGR: